Recombinant Poxviral Vectors Expressing both Rabies and OX40 Proteins, and Vaccines Made Therefrom
AssigneeMerial Limited
InventorsTeshome Mebatsion, Jules Maarten Minke, Frederic David
Life of this patent
Estimating the term…
Abstract
The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus
Claims21
1-34. (canceled)
A recombinant canarypox vector comprising and capable of expressing in vivo in an animal host in need thereof:
- a) two, three or four genes, separately inserted into the C3 and C5 arms of the vector, and each gene encoding the same immunogenic polypeptide, which is selected from a Rabies G, an influenza, an FMDV, a BTV, a PCV2, a PRRSV, a WNV, a Nipah virus, a Hendra virus, a leukemia virus, a leishmania virus, an FIV, an FIPV, a FCV, an AHSV, and a VSV polypeptide;
- and
- b) an OX40L gene, inserted into the C6 arm of the vector, and encoding an OX40L polypeptide, which when expressed in vivo in an animal host functions as an adjuvant for the immunogenic polypeptide(s).
Dependencies are inferred from the claim text.